Published in Cancer Cell on November 06, 2009
Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell (2010) 7.20
Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov (2011) 3.45
Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell (2010) 1.95
Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol (2011) 1.81
Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. J Clin Invest (2011) 1.44
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther (2011) 1.43
A nontranscriptional role for HIF-1α as a direct inhibitor of DNA replication. Sci Signal (2013) 1.17
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell (2013) 1.15
Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev (2014) 1.09
Deletion or Inhibition of the Oxygen Sensor PHD1 Protects against Ischemic Stroke via Reprogramming of Neuronal Metabolism. Cell Metab (2016) 1.05
Early events in the pathogenesis of chronic obstructive pulmonary disease. Smoking-induced reprogramming of airway epithelial basal progenitor cells. Ann Am Thorac Soc (2014) 1.00
Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One (2011) 0.94
Estrogen receptor β sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription. Proc Natl Acad Sci U S A (2013) 0.93
Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke. Free Radic Biol Med (2013) 0.87
Smoking dysregulates the human airway basal cell transcriptome at COPD risk locus 19q13.2. PLoS One (2014) 0.87
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Res (2011) 0.87
A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. Neurobiol Dis (2012) 0.87
Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. Hum Mol Genet (2013) 0.86
EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer. EMBO J (2015) 0.85
Deficiency of a transmembrane prolyl 4-hydroxylase in the zebrafish leads to basement membrane defects and compromised kidney function. J Biol Chem (2010) 0.83
Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. BMC Cancer (2013) 0.83
Regulation of cell proliferation by hypoxia-inducible factors. Am J Physiol Cell Physiol (2015) 0.83
Cell cycle progression in response to oxygen levels. Cell Mol Life Sci (2014) 0.82
Molecular classification of breast cancer. Virchows Arch (2014) 0.80
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Ann N Y Acad Sci (2010) 0.80
Function and expression of prolyl hydroxylase 3 in cancers. Arch Med Sci (2013) 0.79
Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR. Nat Commun (2014) 0.79
PHD2: from hypoxia regulation to disease progression. Hypoxia (Auckl) (2016) 0.78
Suppression of glioma progression by Egln3. PLoS One (2012) 0.78
Acquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes. PLoS Genet (2012) 0.77
PHD1 regulates p53-mediated colorectal cancer chemoresistance. EMBO Mol Med (2015) 0.76
Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges. Hypoxia (Auckl) (2015) 0.76
Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. Biomedicines (2017) 0.76
EglN2 positively regulates mitochondrial function in breast cancer. Mol Cell Oncol (2015) 0.75
EGLN2 and RNF150 genetic variants are associated with chronic obstructive pulmonary disease risk in the Chinese population. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Identification of Small-Molecule PHD2 Zinc Finger Inhibitors that Activate Hypoxia Inducible Factor. Chembiochem (2016) 0.75
Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients. PLoS One (2017) 0.75
New Insights into Protein Hydroxylation and Its Important Role in Human Diseases. Biochim Biophys Acta (2016) 0.75
Inhibition of HIF-prolyl-4-hydroxylases prevents mitochondrial impairment and cell death in a model of neuronal oxytosis. Cell Death Dis (2016) 0.75
EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. Oncotarget (2016) 0.75
Edging toward new therapeutics with cyclin D1 Egl'ng on cancer. Cancer Cell (2009) 0.75
Hyperplasia and hypertrophy of pulmonary neuroepithelial bodies, presumed airway hypoxia sensors, in hypoxia-inducible factor prolyl hydroxylase-deficient mice. Hypoxia (Auckl) (2016) 0.75
A novel prolyl hydroxylase inhibitor protects against cell death after hypoxia. Neurochem Res (2013) 0.75
Role Of Hif2α Oxygen Sensing Pathway In Bronchial Epithelial Club Cell Proliferation. Sci Rep (2016) 0.75
Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells. Cancer Lett (2017) 0.75
Suppression of AGR2 in a TGF-β-induced Smad regulatory pathway mediates epithelial-mesenchymal transition. BMC Cancer (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 19.75
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell (2008) 13.49
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Specific protection against breast cancers by cyclin D1 ablation. Nature (2001) 6.94
JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet (2006) 6.65
HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J (2003) 6.44
Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol (2001) 5.59
Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem (2004) 5.05
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases. Genome Biol (2001) 4.39
The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol (1991) 4.18
E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res (1996) 4.14
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
CDK-independent activation of estrogen receptor by cyclin D1. Cell (1997) 3.85
Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell (2004) 3.77
The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev (2004) 3.59
Requirement for CDK4 kinase function in breast cancer. Cancer Cell (2006) 2.92
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell (2006) 2.91
Cyclin D1 protein expression and function in human breast cancer. Int J Cancer (1994) 2.81
Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol (2006) 2.58
Rescue of cyclin D1 deficiency by knockin cyclin E. Cell (1999) 2.54
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A (2005) 2.54
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood (2007) 2.51
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one? Nat Chem Biol (2007) 2.47
Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci (2003) 2.46
Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol (1997) 2.40
Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood (2007) 2.40
Drosophila cyclin D/Cdk4 requires Hif-1 prolyl hydroxylase to drive cell growth. Dev Cell (2004) 2.02
Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J (2008) 1.95
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood (2007) 1.87
Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol (2005) 1.81
Cyclin D1 and breast cancer. Breast (2006) 1.71
A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol (2009) 1.63
Characterization and comparative analysis of the EGLN gene family. Gene (2001) 1.61
2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg Med Chem Lett (2003) 1.59
Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene (2007) 1.42
A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res (2005) 1.41
Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene (2002) 1.27
Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem (2007) 1.24
Cyclins and breast cancer. Breast Cancer Res Treat (1998) 1.08
Prolyl hydroxylase PHD3 activates oxygen-dependent protein aggregation. Mol Biol Cell (2008) 1.04
Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation. Biochem J (2006) 0.94
Model-based analysis of ChIP-Seq (MACS). Genome Biol (2008) 51.63
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell (2005) 14.32
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell (2008) 14.18
Model-based analysis of tiling-arrays for ChIP-chip. Proc Natl Acad Sci U S A (2006) 13.68
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature (2011) 11.31
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Ductal carcinoma in situ of the breast. N Engl J Med (2004) 6.63
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Molecular determinants for the tissue specificity of SERMs. Science (2002) 6.20
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science (2009) 6.07
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Nucleosome dynamics define transcriptional enhancers. Nat Genet (2010) 5.94
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature (2008) 5.85
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell (2005) 5.38
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A (2007) 5.24
Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A (2009) 5.15
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell (2009) 4.98
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Conserved pathways within bacteria and yeast as revealed by global protein network alignment. Proc Natl Acad Sci U S A (2003) 4.68
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68